title: N-phenacylthiazolium bromide reduces bone fragility induced by nonenzymatic glycation.
abstract: Nonenzymatic glycation (NEG) describes a series of post-translational modifications in the collagenous matrices of human tissues. These modifications, known as advanced glycation end-products (AGEs), result in an altered collagen crosslink profile which impacts the mechanical behavior of their constituent tissues. Bone, which has an organic phase consisting primarily of type I collagen, is significantly affected by NEG. Through constant remodeling by chemical resorption, deposition and mineralization, healthy bone naturally eliminates these impurities. Because bone remodeling slows with age, AGEs accumulate at a greater rate. An inverse correlation between AGE content and material-level properties, particularly in the post-yield region of deformation, has been observed and verified. Interested in reversing the negative effects of NEG, here we evaluate the ability of n-phenacylthiazolium bromide (PTB) to cleave AGE crosslinks in human cancellous bone. Cancellous bone cylinders were obtained from nine male donors, ages nineteen to eighty, and subjected to one of six PTB treatments. Following treatment, each specimen was mechanically tested under physiological conditions to failure and AGEs were quantified by fluorescence. Treatment with PTB showed a significant decrease in AGE content versus control NEG groups as well as a significant rebound in the post-yield material level properties (p<0.05). The data suggest that treatment with PTB could be an effective means to reduce AGE content and decrease bone fragility caused by NEG in human bone.
authors: Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York, United States of America.
authors: Brian S
authors: BS
authors: Bradke
authors: Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York, United States of America.
authors: Deepak
authors: D
authors: Vashishth
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D000818:Animals; D001696:Biomechanical Phenomena; D016723:Bone Remodeling / Q000187:drug effects / Q000235:genetics; D002102:Cadaver; D024042:Collagen Type I / Q000378:metabolism*; D050723:Fractures, Bone / Q000503:physiopathology / Q000628:therapy*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D051381:Rats; D011917:Rats, Inbred Lew; D012266:Ribose / Q000378:metabolism; D013844:Thiazoles / Q000008:administration & dosage*
chemical_list: D024042:Collagen Type I; D017127:Glycation End Products, Advanced; C101705:N-phenacylthiazolium bromide; D013844:Thiazoles; D012266:Ribose